Clarivate’s biosimilars experts routinely analyze key market events via a presentation and commentary, available for playback at any time.

Table of contents

  • Biosimilars - Market Events And Forecast - Market Event Analysis
    • Event Analysis
      • Fujifilm Kyowa Kirin Biologics and Mylan EPD Launch First Adalimumab Biosimilar in Japan
        • April 2021
      • Henlius / Accord Launch the First MAb Biosimilar Developed in China into the European Market
        • The FDA's New Guidance on Insulin Biosimilar Development
          • December 17, 2019
        • Increasing Insurer Coverage of Biosimilars in the United States
          • August 27, 2019
        • The Future Impact of Authorized Generics on the Biologics Market
          • June 20, 2019
        • The Race for Pegfilgrastim Biosimilars in the United States and Europe
          • September 5, 2018
        • Approval of the First ESA Biosimilar in the United States
          • June 25, 2018
        • Ontruzant's EC Approval
          • April 19, 2018
        • AbbVie Settles with Amgen on Humira Patents
          • October 6, 2017
        • A Step Forward for Oncology Monoclonal Antibody Biosimilars
          • October 2, 2017
        • Coherus's CHS-1701 Rejected by the FDA
          • June 22, 2017
        • The EC Approval of Celltrion's Truxima
          • February 27, 2017
        • FDA Approves the First Etanercept Biosimilar: Sandoz’s Erelzi
          • September 1, 2016
        • Remaining U.S. Roadblocks to Inflectra Adoption Postapproval
          • May 23, 2016
        • Ten Years of Biosimilars: Insights from the 14th Annual Biosimilar Medicines Group Congress
          • May 19, 2016
        • Highlights from the 8th Biosimilars Congregation
          • March 24, 2016
        • The EMA Approval of Samsung Bioepis’s Benepali
          • January 25, 2016

    Author(s): Hamzah Aideed, M.Sc.; Yashu Malhotra

    Hamzah Aideed, M.Sc., is a principal analyst on the Biosimilars team at DRG, part of Clarivate. He conducts primary and secondary market research to provide in-depth analysis and insight into the biopharmaceutical industry. Prior to joining DRG, Mr. Aideed was a senior research executive in consulting at McCann Health, specializing in the design and execution of advanced qualitative and quantitative research methodologies for bespoke ad-hoc consulting projects. He holds an M.Sc. in biotechnology, bioprocessing, and business management from the University of Warwick and a B.Sc. in biological chemistry from Aston University in Birmingham.

    Yashu Malhotra, M.Sc., is an associate analyst on the Biosimilars and Onkos teams at DRG, part of Clarivate. Prior to joining DRG, she was a senior analyst in the life sciences at Course5 Intelligence. She also worked in competitive intelligence at WNS Global Services. Ms. Malhotra earned her master’s degree in pharmacy (quality assurance) from India’s Delhi Institute of Pharmaceutical Sciences and Research.